The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary


Mar 4, 2008

Recently I switched from Kaletra/Truvada to Lexiva/Norvir and Truvada. My ID doc wants me to dose with 700mg Lexiva + 100mg Norvir in the morning, followed by 700 mg of Lexiva in the evening only. My VL was undectable and CD4 was 900 when the switch was made this past week. This is not an approved dosing routine, but our objective was to lower the norvir as I have noticed my skin appears red like a sunburn which we suspect is related to the Norvir. My ID doc indicates that there are successful studies using this routine. Any thoughts, will I maintain a sufficient plasma level of Lexiva to maintain an undectable VL?

Response from Dr. Young

Thanks for your post

The use of 100 mg ritonavir (Norvir) with 1400 mg fosamprenavir (Lexiva, Telzir) is indeed FDA approved for first-line use. There are a number of studies that support this dosing, though for simplicity, the entire 3 pill PI regimen (with Truvada) can be taken at once.

Be well, BY


  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint